Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › EIKN

Eikon Therapeutics

EIKN Lead: Phase 2 5 Biotech Distilled articles ↓ 23 filings & releases ↓ Cash $143M (Jun 30, 2026) ↓ 5 verdicts ↓ 6 timing quotes ↓
Oncology Small Molecule

Market cap $320M 54.2M shares (10-Q, Aug 3, 2026) × $5.90 close Nov 6, 2026

Most recent annual filing: 2026-03-30

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. EIK1004 readout2H 2026EIK1004 readout, 2H 2026, notable
  2. TeLuRide-008 interim2H 2027TeLuRide-008 interim, 2H 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (13 active programs)

Technology platforms

SMT

Single molecule tracking platform integrating custom-engineered super-resolution microscopy, bespoke automation, advanced data science ML/AI tools, and petabyte-scale data processing. Used to identify and validate novel targets, elucidate mechanisms of action, and accelerate drug candidate identification. Focus areas: oncology and neurologic disease.

single molecule tracking

Proprietary single molecule tracking system used to enable drug discovery and development of internally derived novel oncology therapies; EIK1005 emerged through application of this advanced imaging discovery platform.

Capital (as filed)

Cash
$143M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$389M Jun 30, 2026
Operating cash flow
−$65.0M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$531M cash, runway second half of 2027 per the update of Oct 26, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on Eikon Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-08-05 Watch Eikon Therapeutics (EIKN) — Scientific Deep Dive for EIK1001, EIK1003, and Pipeline Products Un-patentable lead asset, unresolved licensor payment dispute, and single-arm confidence intervals that swallow the standard-of-care benchmark keep this on the sidelines until the randomized TeLuRide-006 melanoma interim reads out.
  2. 2026-08-12 Watch UPDATE: Eikon Therapeutics (EIKN) - The DMC Picked the Low Dose DMC dose selection confirms trial continuation and removes catastrophic-interim risk but discloses zero efficacy data, leaving the named trigger — the randomized melanoma efficacy interim — unfired.
  3. 2026-08-14 Watch UPDATE: Eikon Therapeutics (EIKN) - The Dispute Quietly Died, the Burn Did Not Seven and Eight licensor dispute resolved (removing one bear pillar), but burn accelerated 77% YoY and no efficacy data changed; named trigger remains the randomized melanoma interim.
  4. 2026-10-24 Watch UPDATE: Eikon Therapeutics (EIKN) - The Undercard Fight ESMO day-one data shows EIK1004 blood-sparing thesis confirmed but EIK1003 and EIK1005 disappoint; EIK1001 valuation driver untouched and randomized melanoma interim still undated.
  5. 2026-10-27 Watch UPDATE: Eikon Therapeutics (EIKN) - The Durability Test Splits Down the Middle Non-squamous durability resolved below KEYNOTE-189 benchmark and first randomized NSCLC read slipped to 2H 2027, weakening the NSCLC leg and making a dilutive financing before randomized proof more likely; named trigger still unfired.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (6 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (23)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 10, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)